GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
‘We want to build a group that will outlive us all’ – James Barbara
James Barbara brought a group of major businesses together under a new corporate identity.
LifeStar Insurance appoints economist Jean Paul Fabri as Interim Acting CEO
His appointment follows the departure of Jonathan Camilleri as CEO.
Building on Ferraracasa’s legacy: Third generation, next chapter
Joining an established family business brings a different challenge to building one from the ground up. The foundations already exist, ...
‘I dreamed of moving to Malta 20 years ago’: iQrypto CEO
Quantum tech firm iQrypto is set to expand its operations to Malta.
